[Therapeutic approaches in hypertrophic cardiomyopathy: from symptom relief to precision therapy].

IF 0.7 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS
Alessia Argirò, Mattia Zampieri, Alberto Marchi, Annamaria Del Franco, Eszter Dalma Pàlinkàs, Giulia Biagioni, Chiara Chiti, Carlotta Mazzoni, Alessandra Fornaro, Mattia Targetti, Francesco Cappelli, Iacopo Olivotto
{"title":"[Therapeutic approaches in hypertrophic cardiomyopathy: from symptom relief to precision therapy].","authors":"Alessia Argirò,&nbsp;Mattia Zampieri,&nbsp;Alberto Marchi,&nbsp;Annamaria Del Franco,&nbsp;Eszter Dalma Pàlinkàs,&nbsp;Giulia Biagioni,&nbsp;Chiara Chiti,&nbsp;Carlotta Mazzoni,&nbsp;Alessandra Fornaro,&nbsp;Mattia Targetti,&nbsp;Francesco Cappelli,&nbsp;Iacopo Olivotto","doi":"10.1714/4100.40979","DOIUrl":null,"url":null,"abstract":"<p><p>Hypertrophic cardiomyopathy is the most common genetic cardiomyopathy. Main complications include the development of arrhythmias and heart failure, and the latter may be triggered by left ventricular outflow tract obstruction. The treatment of left ventricular outflow tract obstruction includes pharmacological therapies (beta-blockers, calcium channel blockers, disopyramide) and septal reduction therapies (alcohol septal ablation, surgical myectomy). Myosin inhibitors represent a new therapeutic opportunity and in recent clinical trials proved effective in symptom relief, improvement of functional capacity and quality of life in patients with obstructive hypertrophic cardiomyopathy. In this narrative review we will summarize the available and under development therapeutic approaches for hypertrophic cardiomyopathy.</p>","PeriodicalId":12510,"journal":{"name":"Giornale italiano di cardiologia","volume":"24 10","pages":"792-799"},"PeriodicalIF":0.7000,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Giornale italiano di cardiologia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1714/4100.40979","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Hypertrophic cardiomyopathy is the most common genetic cardiomyopathy. Main complications include the development of arrhythmias and heart failure, and the latter may be triggered by left ventricular outflow tract obstruction. The treatment of left ventricular outflow tract obstruction includes pharmacological therapies (beta-blockers, calcium channel blockers, disopyramide) and septal reduction therapies (alcohol septal ablation, surgical myectomy). Myosin inhibitors represent a new therapeutic opportunity and in recent clinical trials proved effective in symptom relief, improvement of functional capacity and quality of life in patients with obstructive hypertrophic cardiomyopathy. In this narrative review we will summarize the available and under development therapeutic approaches for hypertrophic cardiomyopathy.

【肥厚型心肌病的治疗方法:从症状缓解到精准治疗】。
肥厚型心肌病是最常见的遗传性心肌病。主要并发症包括心律失常和心力衰竭,后者可能由左心室流出道阻塞引发。左心室流出道梗阻的治疗包括药物治疗(β受体阻滞剂、钙通道阻滞剂、二吡喃胺)和间隔缩小治疗(酒精性间隔消融术、手术性髓鞘切除术)。肌球蛋白抑制剂代表了一个新的治疗机会,最近的临床试验证明,肌球蛋白抑制剂在阻塞性肥厚型心肌病患者的症状缓解、功能能力改善和生活质量方面有效。在这篇叙述性综述中,我们将总结肥厚型心肌病的可用和正在开发的治疗方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Giornale italiano di cardiologia
Giornale italiano di cardiologia CARDIAC & CARDIOVASCULAR SYSTEMS-
CiteScore
1.10
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信